Cytokinetics grants 20,807 stock options at USD 75.85 under inducement plan

Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

0.00
  • Cytokinetics granted inducement equity awards on May 15, 2026 to eight new employees who started in April and May 2026.
  • Stock options covered 20,807 shares with an exercise price of USD 75.85 per share, matching the May 15 closing price; the options have a 10-year term.
  • Options vest over four years, with 25% vesting on the first anniversary of the grant date, then monthly vesting over the next 36 months.
  • Restricted stock units covered 13,793 shares; vesting runs over three years with 40% after year one, 40% after year two, then 20% after year three.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605181600PRIMZONEFULLFEED9722429) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.